As US biosimilar activity rises, is the first filing imminent?
This article was originally published in Scrip
Executive Summary
With the launch of biosimilar Remicade marking another reference point in Europe's expanding biosimilars landscape, the question arises: When can we expect the first biosimilar filing in the US? No one's saying, but the steady rise in sponsor-FDA activity over the past few years suggests it may not be long now.